

Web of Science ResearcherID: ACV-3844-2022
ORCID: 0000-0001-7057-7815

H-Index – 15

Rezumat al articolelor ca reviewer – Numar de manuscrise in jurnale- Septembrie 2019-Mai 2025

- (6) Frontiers in Oncology (4) Plos One
- (1) International Journal of Cancer (1) Frontiers in Endocrinology
- (1) BJU International (1) Medicine
- (1) Journal of Computational Biology (1) Journal of Clinical Medicine
- (1) Life (1) Therapeutic Advances in Urology

Editor: Journal of Clinical Medicine – Special Issue: Inovations in Minimally Invasive Surgery (MIS) in Urology IF: 3.0, Cite Score 5.7

Review Editor pentru Cancer Endocrinology, Frontiers in Endocrinology IF: 3.9, Cite Score 5.7

Editorial Review Board Member for Therapeutics Advances in Urology IF: 2.6, Cite Score 3.9

Publicații până în Mai 2025: Reviste ISI cu factor de impact

a. Articole:

1. Contieri, R.; Claps, F.; Hurle, R.; Buffi, N.M.; Lughezzani, G.; Lazzeri, M.; Aveta, A.; Pandolfo, S.; Porpiglia, F.; Fiori, C.; et al. Impact of Smoking Exposure on Disease Progression in High Risk and Very High-Risk Nonmuscle Invasive Bladder Cancer Patients Undergoing BCG Therapy. *Urol. Oncol.* **2024**, S1078-1439(24)00748-8, doi:10.1016/j.urolonc.2024.11.015. 15*1+2,4/52=0,98
2. Barone, B.; Amicuzi, U.; Massanova, M.; Napolitano, L.; Reccia, P.; Mirto, B.F.; Balsamo, R.; Giudice, F.D.; Ferro, M.; Busetto, G.M.; et al. The Correlation Between Body Mass Index and Prostate Volume: A Retrospective Analysis of Pre and Postoperative Measurements in Prostate Cancer Patients. *The Prostate* **2024**, doi:10.1002/pros.24845. 15*1+2,4/19=2,68
3. Tătaru, O.S.; Ferro, M.; Marchioni, M.; Vecchia, A.; Coman, O.; Lasorsa, F.; Brescia, A.; Crocetto, F.; Barone, B.; Catellani, M.; et al. HoloLens® Platform for Healthcare Professionals Simulation Training, Teaching, and Its Urological Applications: An up-to-Date Review. *Ther. Adv. Urol.* **2024**, 16, 17562872241297554, doi:10.1177/17562872241297554. 15*1+2,6=54 *
4. Ferro, M.; Tataru, O.S.; Fallara, G.; Fiori, C.; Manfredi, M.; Claps, F.; Hurle, R.; Buffi, N.M.; Lughezzani, G.; Lazzeri, M.; et al. Assessing the Influence of Smoking on Inflammatory Markers in Bacillus Calmette-Guérin Response among Bladder Cancer Patients: A Novel Machine-Learning Approach. *Minerva Urol. Nephrol.* **2024**, doi:10.23736/S2724-6051.24.05876-2. 15*1+4,9/54=1,63
5. Contieri, R.; Claps, F.; Hurle, R.; Buffi, N.M.; Lughezzani, G.; Lazzeri, M.; Aveta, A.; Pandolfo, S.; Porpiglia, F.; Fiori, C.; et al. Impact of Smoking Exposure on Disease Progression in High Risk and Very High-Risk Nonmuscle Invasive Bladder Cancer Patients Undergoing BCG Therapy. *Urol. Oncol.* **2024**, S1078-1439(24)00748-8, doi:10.1016/j.urolonc.2024.11.015. 15*1+2,4/52=0,98
6. Amicuzi, U.; Grillo, M.; Olivetta, M.; Tammara, S.; Napolitano, L.; Reccia, P.; De Luca, L.; Rubinacci, A.; Della Rosa, G.; et al. Exploring the Multifactorial Landscape of Penile Cancer: A Comprehensive Analysis of Risk Factors. *Diagn. Basel Switz.* **2024**, 14, 1790, doi:10.3390/diagnostics14161790. 15*1+3/27=2,22
7. Mirto, B.F.; Barone, B.; Balsamo, R.; Abate, M.; Caputo, V.F.; Sciarra, A.; Calogero, A.; Romano, L.; Napolitano, L.; Sciorio, C.; et al. Early and Late Post-Operational Complications in Different Orthotopic Neobladder Surgical Approaches: A Systematic Review. *Surg. Oncol.* **2024**, 55, 102090, doi:10.1016/j.suronc.2024.102090. 15*1+3,4/20=3,3
8. Tresh, A.S.; Del Giudice, F.; Li, S.; Basran, S.; Belladelli, F.; De Berardinis, E.; Asero, V.; Ferro, M.; Tataru, S.; Maria Busetto, G.; et al. The Impact of Venous Thromboembolism on Upper Tract Urothelial Carcinomas Undergoing Open or Minimally Invasive Radical Nephroureterectomy in the USA: Perioperative Outcomes and Health Care Costs from Insurance Claims Data. *Eur. Urol. Focus* **2024**, S2405-4569(24)00021-X, doi:10.1016/j.euf.2024.02.004. 15*1+5,4/26=3,69
9. Porreca, A.; Di Nicola, M.; Lucarelli, G.; Dorin, V.M.; Soria, F.; Terracciano, D.; Mistretta, F.A.; Luzzago, S.; Buonerba, C.; Cantiello, F.; et al. Time to Progression Is the Main Predictor of Survival in Patients with High-Risk Nonmuscle Invasive Bladder Cancer: Results from a Machine Learning-Based Analysis of a Large Multi-Institutional Database. *Urol. Oncol.* **2024**, 42, 69.e17-69.e25, doi:10.1016/j.urolonc.2024.01.001. 15*1+2,4/38=1,34
10. Busetto, G.M.; Checchia, A.; Recchia, M.; Tocci, E.; Falagario, U.G.; Annunziata, G.; Annesse, P.; d'Altilla, N.; Mancini, V.; Ferro, M.; et al. Minimally Invasive Surgical Therapies (MISTs) for Lower Urinary Tract Symptoms (LUTS): Promise or Panacea? *Asian J. Androl.* **2023**, 26, 135–143, doi:10.4103/aja202357. 15*1+3/19=3,15
11. Ferro, M.; Rocco, B.; Maggi, M.; Lucarelli, G.; Falagario, U.G.; Del Giudice, F.; Crocetto, F.; Barone, B.; La Civita, E.; Lasorsa, F.; et al. Beyond Blood Biomarkers: The Role of SelectMDX in Clinically Significant Prostate Cancer Identification. *Expert Rev. Mol. Diagn.* **2023**, 23, 1061–1070, doi:10.1080/14737159.2023.2277366. 15*1+3/15=4
12. Ferro, M.; Chiujdea, S.; Vartolomei, M.D.; Bove, P.; Porreca, A.; Busetto, G.M.; Del Giudice, F.; Antonelli, A.; Foschi, N.; Racioppi, M.; et al. Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. *Clin. Genitourin. Cancer* **2024**, 22, 27–37, doi:10.1016/j.clgc.2023.08.001. 15*1+3/40=1,5

13. Ferro, M.; Falagario, U.G.; Barone, B.; Maggi, M.; Crocetto, F.; Busetto, G.M.; Giudice, F.D.; Terracciano, D.; Lucarelli, G.; Lasorsa, F.; et al. Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement. *Diagn. Basel Switz.* **2023**, *13*, 2308, doi:10.3390/diagnostics13132308. 15*1+3=60 *
14. Lasorsa, F.; Rutigliano, M.; Milella, M.; Ferro, M.; Pandolfo, S.D.; Crocetto, F.; Tataru, O.S.; Autorino, R.; Battaglia, M.; Ditunno, P.; et al. Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma. *J. Clin. Med.* **2023**, *12*, 3888, doi:10.3390/jcm12123888. 15*1+3/11=5,45
15. Ferro, M.; Crocetto, F.; Tataru, S.; Barone, B.; Dolce, P.; Lucarelli, G.; Sonpavde, G.; Musi, G.; Antonelli, A.; Vecchia, A.; et al. Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis. *Clin. Genitourin. Cancer* **2023**, *21*, 574–583, doi:10.1016/j.clgc.2023.05.017. 15*1+2,3/23=2,15
16. Ferro, M.; Crocetto, F.; Barone, B.; Del Giudice, F.; Maggi, M.; Lucarelli, G.; Busetto, G.M.; Autorino, R.; Marchioni, M.; Cantiello, F.; et al. Artificial Intelligence and Radiomics in Evaluation of Kidney Lesions: A Comprehensive Literature Review. *Ther. Adv. Urol.* **2023**, *15*, 17562872231164803, doi:10.1177/17562872231164803. 15*1+2,6=54 *
17. Barone, B.; Mirto, B.F.; Falcone, A.; Del Giudice, F.; Aveta, A.; Napolitano, L.; Del Biondo, D.; Ferro, M.; Busetto, G.M.; Manfredi, C.; et al. The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial. *J. Clin. Med.* **2023**, *12*, 2784, doi:10.3390/jcm12082784. 15*1+3/22=2,72
18. Lasorsa, F.; di Meo, N.A.; Rutigliano, M.; Milella, M.; Ferro, M.; Pandolfo, S.D.; Crocetto, F.; Tataru, O.S.; Autorino, R.; Battaglia, M.; et al. Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. *Biomedicines* **2023**, *11*, 1071, doi:10.3390/biomedicines11041071. 15*1+3,9/12=6,12
19. Vartolomei, L.; Cotruș, A.; Tătaru, S.O.; Vartolomei, M.D.; Man, A.; Ferro, M.; Stanciu, C.; Sin, A.I.; Shariat, S.F. Lower Urinary Tract Symptoms Are Associated with Clinically Relevant Depression, Anxiety, and Stress Symptoms. *Aging Male Off. J. Int. Soc. Study Aging Male* **2022**, *25*, 62–66, doi:10.1080/13685538.2022.2040981. 15*1+2,6/9=6
20. Del Giudice, F.; Asero, V.; Bologna, E.; Scornajenghi, C.M.; Carino, D.; Dolci, V.; Viscuso, P.; Saliccia, S.; Sciarra, A.; D'Andrea, D.; et al. Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis. *Cancers* **2023**, *15*, 1937, doi:10.3390/cancers15071937. 15*1+4,5/38=2,17
21. Ferro, M.; Musi, G.; Marchioni, M.; Maggi, M.; Vecchia, A.; Del Giudice, F.; Barone, B.; Crocetto, F.; Lasorsa, F.; Antonelli, A.; Schips, L.; Autorino, R.; Busetto, G.M.; Terracciano, D.; Lucarelli, G.; Tataru, O.S. Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects. *Int. J. Mol. Sci.* **2023**, *24*, 4615. <https://doi.org/10.3390/ijms24054615> 15*1+4,9=88,5 *
22. Tataru, O.S.; Marchioni, M.; Crocetto, F.; Barone, B.; Lucarelli, G.; Del Giudice, F.; Busetto, G.M.; Vecchia, A.; Lo Giudice, A.; Russo, G.I.; Luzzago, S.; Piccinelli, M.L.; Vartolomei, M.D.; Musi, G.; Ferro, M. Molecular Imaging Diagnosis of Renal Cancer Using ^{99m}Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques. *Diagnostics* **2023**, *13*, 593. <https://doi.org/10.3390/diagnostics13040593> 15*1+3=60 *
23. Lasorsa, F.; di Meo, N.A.; Rutigliano, M.; Ferro, M.; Terracciano, D.; Tataru, O.S.; Battaglia, M.; Ditunno, P.; Lucarelli, G. Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer. *Int. J. Mol. Sci.* **2023**, *24*, 910. https://doi.org/10.3390/ijms2402091015*1+4,9/9=9,83
24. Contieri, R.; Hurler, R.; Paciotti, M.; Casale, P.; Saita, A.; Porpiglia, F.; Fiori, C.; Barone, B.; Crocetto, F.; Lucarelli, G.; et al. Accuracy of the European Association of Urology (EAU) NMIBC 2021 Scoring Model in Predicting Progression in a Large Cohort of HG T1 NMIBC Patients Treated with BCG. *Minerva Urol. Nephrol.* **2022**, doi:10.23736/S2724-6051.22.04953-9. 15*1+4,9/38=2,32
25. Ferro, M.; de Cobelli, O.; Musi, G.; Del Giudice, F.; Carrieri, G.; Busetto, G.M.; Falagario, U.G.; Sciarra, A.; Maggi, M.; Crocetto, F.; et al. Radiomics in Prostate Cancer: An up-to-Date Review. *Ther. Adv. Urol.* **2022**, *14*, 17562872221109020, doi:10.1177/17562872221109020. 15*1+1,86=42,9 *
26. Aveta, A.; Cacciapuotì, C.; Barone, B.; Di Zazzo, E.; Del Giudice, F.; Maggi, M.; Ferro, M.; Terracciano, D.; Busetto, G.M.; Lucarelli, G.; et al. The Impact of Meat Intake on Bladder Cancer Incidence: Is It Really a Relevant Risk? *Cancers* **2022**, *14*, 4775, doi:10.3390/cancers1419477515*1+2,5/24=2,18
27. Ferro, M.; Barone, B.; Crocetto, F.; Lucarelli, G.; Busetto, G.M.; Del Giudice, F.; et al. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. *UrolOncol.* **2022**, Jun 5;S1078-1439(22)00186-7. DOI: [10.1016/j.urolonc.2022.05.01615*1+2,7/34=1,63](https://doi.org/10.1016/j.urolonc.2022.05.01615*1+2,7/34=1,63)
28. Vartolomei, L.; Cotruș, A.; Tătaru, S.O.; Vartolomei, M.D.; Man, A.; Ferro, M.; et al. Lower urinary tract symptoms are associated with clinically relevant depression, anxiety, and stress symptoms. *Aging Male Off J IntSoc Study Aging Male.* **2022**, Dec;25(1):62–6. DOI: [10.1080/13685538.2022.204098115*1+2,6/9=6](https://doi.org/10.1080/13685538.2022.204098115*1+2,6/9=6)
29. Ferro, M.; de Cobelli, O.; Vartolomei, M.D.; Lucarelli, G.; Crocetto, F.; Barone, B.; Sciarra, A.; Del Giudice, F.; Muto, M.; Maggi, M.; Carrieri, G.; Busetto, G.M.; Falagario, U.; Terracciano, D.; Cormio, L.; Musi, G.; Tataru, O.S. Prostate Cancer Radiogenomics—From Imaging to Molecular Characterization. *International Journal of Molecular Sciences.* **2021**; *22*(18):9971. https://doi.org/10.3390/ijms2218997115*1+6.208=108,12*

30. di Meo, N.A.; Loizzo, D.; Pandolfo, S.D.; Autorino, R.; Ferro, M.; Porta, C.; Stella, A.; Bizzoca, C.; Vincenti, L.; Crocetto, F.; Tataru, O.S.; Rutigliano, M.; Battaglia, M.; Ditunno, P.; Lucarelli, G. Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer. *Int. J. Mol. Sci.* **2022**, *23*, 4173. <https://doi.org/10.3390/ijms23084173> 15*1+5,6/15=6,6

Publicații până în 2025: Reviste ISI fără factor de impact (echivalate BDI) și articole ISI echivalate BDI

1. **Tătaru OS, Martha O, Crocetto F, et al. Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study. *Future Sci OA* 2021; FSO745.(3 puncte echivalare) ****
2. Loizzo D, di Meo NA, Peluso MR, Rutigliano M, Matera M, Miacola C, Palella G, Tedeschi M, Spilotros M, Ferro M, Tătaru OS, Vartolomei MD, Vincenti L, Ditunno P, Battaglia M, Lucarelli G. Novel Insights into the Molecular Mechanisms of Ischemia/Reperfusion Injury in Kidney Transplantation. *Transplantation*. 2021; 2(2):191-207. <https://doi.org/10.3390/transplantation20200180,93>
3. Barone, B.; Napolitano, L.; Reccia, P.; Calace, F.P.; De Luca, L.; Olivetta, M.; Stizzo, M.; Rubinacci, A.; Della Rosa, G.; Lecce, A.; et al. Advances in Urinary Diversion: From Cutaneous Ureterostomy to Orthotopic Neobladder Reconstruction-A Comprehensive Review. *J. Pers. Med.* **2024**, *14*, 392, doi:10.3390/jpm14040392. 0,53
4. **Tătaru OS, Bujoreanu EC, Coste BO, et al. Robotic and 3D laparoscopic radical nephroureterectomy with en bloc specimen excision (kidney, ureter, bladder cuff excision and extended lymphadenectomy) – Case report. *Int J Surg Case Rep* 2022; 92: 106902. 15*1+0,6=24(3 puncte echivalare) ****
5. **Tătaru OS, Vartolomei MD, Rassweiler JJ, Virgil O, Lucarelli G, Porpiglia F, et al. Artificial Intelligence and Machine Learning in Prostate Cancer Patient Management-Current Trends and Future Perspectives. *Diagnostics (Basel)*. 2021 Feb 20;11(2). 15*1+3,94=59,1(3 puncte echivalare) ****
6. Ferro M, **Tătaru OS**, Musi G, Lucarelli G, Abu Farhan AR, Cantiello F, Damiano R, Hurle R, Contieri R, Busetto GM, Carrieri G, Cormio L, Del Giudice F, Sciarra A, Perdonà S, Borghesi M, Terrone C, La Civita E, Bove P, Autorino R, Muto M, Crisan N, Marchioni M, Schips L, Soria F, Terracciano D, Papalia R, Crocetto F, Barone B, Russo GI, Luzzago S, Ludovico GM, Vartolomei MD, Mistretta FA, Mirone V, de Cobelli O. Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guérin Immunotherapy. *Diagnostics*. 2022; 12(3):586. <https://doi.org/10.3390/diagnostics12030586> 15*1+3,61=69,15(3 puncte echivalare) **

b. Cărți

1. Biomarkeri cu semnificație clinică în uro-oncologie, volumul I - Mihai Dorin Vartolomei, Anca Ileana Sin, Daniel Porav-Hodade, Octavian Sabin Tataru [Internet]. [cited 2021 Apr 15]. Available from: <https://www.librariadelfin.ro/carte/biomarkeri-cu-semnificatie-clinica-in-uro-oncologie-volumul-i-mihai-dorin-vartolomei-anca-ileana-sin-daniel-porav-hodade-octavian-sabin-tataru-i91377>
2. Biomarkeri Cu Semnificație Clinică în Uro-Oncologie. Volumul II - - Mihai Dorin Vartolomei, University Press (Umf) - 22,29 Lei - LibrariaOnline.Ro Available online: https://www.librariaonline.ro/medicina_si_farmacie/medicina_umana/diverse/biomarkeri_cu-semnificatie-clinica_in_uro-oncologie-volumul_ii-vartolomei_mihai_dorin-university_press_umf-p10173151 (accessed on 10 January 2023).

c. Teza de doctorat

Studii doctorale I.O.S.U.D UMFST George Emil Palade Târgu Mures

Doctor în medicină

Confirmat prin O.M.E. 6415/15.12.2022

Titlul tezei: Factori clinic-biologici și patologici cu rol diagnostic și prognostic în cancerul de prostată

*publicații ISI cu factor de impact bold-uite – articole autor principal

**publicații cu caracter egalitate – articole ISI echivalate BDI